Monthly Newsletter

Cenix BioScience GmbH, a leading contract research organization specializing in RNA interference- (RNAi) and microRNA- (miRNA) based drug discovery, today announced that it is growing its R&D operations by establishing a new subsidiary in Flanders, Belgium.

The new subsidiary company, named Cenix BioScience BVBA, will be wholly owned by its Dresden-based parent, and will help accelerate the development of the company's R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi . Through these programs, Cenix is working to improve the in vivo applicability of siRNA technology by testing novel delivery solutions including its own proprietary DARE^TM technology. The expansion comes as part of a major growth and diversification initiative ongoing since 2008 to broaden the company's range of activities beyond the cell-based RNAi services that have established Cenix as a global leader in various applications of RNAi screening over the past 11 years.

"We are very excited to start this important new phase in our company's development," said Dr. Christophe Echeverri, CEO/CSO of Cenix. "This opportunity comes as the result of many years of hard work by past and present staff. It also arises at a particularly strategic time in the maturation of the RNAi field, which we are eager to help drive further forward in the years to come, now through both our original Dresden team and our new Flanders unit."

The new subsidiary will employ new staff, and so, details on the new Flanders-based job openings can be found at http://www.cenix-bioscience.com/careers/.

About Cenix BioScience GmbH - www.cenix-bioscience.com
Now in its 12th year, Cenix BioScience is a contract research organization specialized in combining advanced applications of RNAi with high content phenotypic analyses to enhance and accelerate the discovery and pre-clinical development of novel therapeutics. Cenix has built up a dominant track record in this field, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully customized, cutting-edge research offerings covering a wide range of disease fields including oncology, cardiovascular, metabolic, neurological and infectious diseases. The well-established core capabilities in high throughput siRNA screening and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, and are now complemented by miRNA screening, and in vivo RNAi applications using synthetic siRNAs. As such, Cenix is a mature and fully proven industrial research provider, applying the highest of scientific best practices and offering a breadth and depth of specialist expertise second to none worldwide. For more information, please contact Cenix or visit the company's web site: www.cenix-bioscience.com